PDL BioPharma (PDLI +1.1%) has closed the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA to Stanley Capital, for the total value consideration of up to $52.83M in cash, $4.58M greater than previously announced.